Introduction {#Sec1}
============

Approximately 20 % of the patients with an abdominal aortic aneurysm (AAA) have a positive family history for aneurysms, suggesting a genetic predisposition for AAA in these families (Rossaak et al. [@CR40]; Salo et al. [@CR41]; van de Luijtgaarden et al. [@CR49]). The genetic aortic aneurysm syndromes Marfan, Loeys--Dietz, and aneurysms-osteoarthritis (AOS), involving the *FBN1*, *TGFBR1*, *TGFBR2*, *TGFB2*, and *SMAD3* genes were first identified in patients with pathologic dilatation or aneurysm of the thoracic aorta with multisystem overlapping cardiovascular, skeletal and ocular manifestations (Boileau et al. [@CR4]; Cook et al. [@CR7]; Dietz et al. [@CR8]; Loeys et al. [@CR24]; van de Laar et al. [@CR47]). The genetic defects in these syndromes affect the integrity of the elastic medial layer by inference with the transforming growth factor-beta (TGF-β) pathway (Boileau et al. [@CR4]; Judge and Dietz [@CR18]; Lindsay et al. [@CR22]; Loeys et al. [@CR23]; ten Dijke and Arthur [@CR45]). The wide range of variably expressed features in these rare autosomal dominantly inherited syndromic forms of familial thoracic aneurysm includes pectus- and/or spinal deformities, joint laxity, and skin translucency and specifically for AOS, osteoarthritis and for the Loeys--Dietz syndrome, hypertelorism, bifid uvula or cleft palate and arterial tortuosity. Vascular tortuosity, ascending aortic aneurysm, joint laxity and pectus excavatum are also main features of the *EFEMP2*-related autosomal recessive juvenile cutis laxa syndrome (Hucthagowder et al. [@CR14]; Kappanayil et al. [@CR19]).

In another group of families with thoracic aneurysm without distinct clinical features, genetic defects were identified in the so-called non-syndromic familial thoracic aneurysm genes including the *MYH11*, *MYLK* and *ACTA2* that affect smooth muscle cell (SMC) functioning (Kuang et al. [@CR20]; Pannu et al. [@CR32]; Renard et al. [@CR38]; Wang et al. [@CR50]). These may also affect TGF-β signaling, like *ACTA2* mutations, occurring in 16 % of patients with familial thoracic aortic aneurysm and in sporadic thoracic aortic aneurysms and dissections associated with medial degeneration, focal medial smooth muscle cell hyperplasia and proliferation, and stenotic arteries in the vaso-vasorum (Guo et al. [@CR12]; Morisaki et al. [@CR30]; Renard et al. [@CR38]). A recent review estimates that approximately 20 % of familial thoracic aneurysm cases could be explained by a mutation in one of the thoracic aneurysm genes (Pomianowski and Elefteriades [@CR36]). Establishing the exact contribution of each of these genes in (familial) thoracic aneurysms has been hampered by the overlap in clinical features. Occasionally isolated abdominal aortic aneurysms have been observed in families with familial syndromic and non-syndromic thoracic aneurysm. Therefore, genes associated with the familial thoracic aortic aneurysm may play a role in the degenerative changes of the extracellular matrix of the abdominal aortic wall underlying the formation of AAA. For this reason, we decided to screen AAA patients for variants in the transforming growth factor-beta pathway genes *EFEMP2, FBN1, SMAD3, TGBF2, TGFBR1*, *TGFBR2,* smooth muscle cells genes *ACTA2, MYH11* and *MYLK,* as well as the vascular Ehlers--Danlos gene *COL3A1*, which is associated with vascular fragility (Pepin et al. [@CR33]). In addition, we investigated the previously reported association between abdominal aneurysm and the c.665C\>T variant in *MTHFR* (Thompson et al. [@CR46]). We report all the variants found in these analyses, except those classified as clearly not pathogenic (benign). The presented description of variants will convey relevance for classification of variants in future diagnostic setting.

Materials and methods {#Sec2}
=====================

The study complied with the declaration of Helsinki and was approved by the Institutional Review Board (MEC-2013-265).

Study population {#Sec3}
----------------

The study population consisted of 155 AAA patients referred for genetic counseling between January 2009 and December 2013 to the Department of Clinical Genetics at the Erasmus University Medical Center in Rotterdam, the Netherlands. Abdominal aortic aneurysm was defined as an external infrarenal abdominal aortic diameter ≥30 mm (Moll et al. [@CR29]). Patients were classified as familial AAA when at least one first-degree relative (i.e., parent, sibling or child) was confirmed by medical records to be diagnosed with an aortic aneurysm (*n* = 99, 81 male). Patients reporting only affected second- or third-degree relatives were also classified as sporadic AAA, because the reporting of medical information of second- or third-degree relatives was considered less reliable (Andreasen et al. [@CR1]). Patients without an affected first-degree relative were classified as sporadic AAA (*n* = 56, 46 male). In case of familial AAA, the first family member diagnosed with AAA was included as index in the study. Cases of concordant twins were considered as familial AAA. Genetic evaluation of the AAA patients was performed by a clinical geneticist and included ascertainment of a detailed family history and physical examination. All patients consented to DNA testing.

DNA analysis and classification of variants {#Sec4}
-------------------------------------------

Sanger sequencing of all coding exons and exon--intron boundaries in *ACTA2* (NM_001613.1)*, COL3A1* (NM_000090.3), *EFEMP2* (NM_016938.3), *FBN1* (NM_000138.3)*, MYH11* (NM_001040113.1)*, MYLK* (NM_053025.3)*, SMAD3* (NM_005902.3), *TGFB2* (NM_001135599.2), *TGFBR1* (NM_004612.2) and *TGFBR2* (NM_001024847.2) was performed at the certified laboratories of the Departments of Clinical Genetics of the Erasmus University Medical Center in Rotterdam and the VU Medical Center in Amsterdam. Patients were tested for the p.Ala222Val variant in *MTHFR* (NM_005957.4) at the Department of Clinical Genetics at the University Hospital in Nijmegen, The Netherlands.

Assessment of the pathogenic effect of genetic variants was performed according to the guidelines currently used in the Rotterdam laboratory for DNA diagnostics with the use of Alamut Interactive Biosoftware (Rouen, France). This software incorporates SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder for the prediction of splicing variants and the programs Align GVGD, SIFT, Mutation Taster, PolyPhen-2 and KDv4 for in silico prediction of the effect of amino acid changes. Additionally, it gives population frequencies for dbSNP and ESP, and shows whether or not a variant has been reported before in Human Gene Mutation Database (HGMD). The Rotterdam classification system of variants was adapted from the sequence variation classification proposed by Plon et al. ([@CR35]). The criteria for classification of variants included the allele frequency in the dbSNP/ESP (cutoff 0.01), predicted effects on splicing, the in silico prediction of effect on the protein and previously described links to disease. Exonic variants remote from wild-type splice donor and acceptor sites were assessed to have no effect on splicing. For each variant present in HGMD the supporting evidence was reviewed and we evaluated whether previous reports linking specific variants to aneurysm were supported by functional studies or expression assays. Additionally, a variant only predicted by in silico prediction to be pathogenic would not automatically be classified as such because of lack of functional evidence. This resulted in categorizing variants into five classes: pathogenic, likely pathogenic, unknown significance (VUS), likely benign, and benign (Table [1](#Tab1){ref-type="table"}; Richards et al. [@CR39]). All variants expect those classified as benign were reported in this paper. A single previous description of a variant in a patient was not considered as sufficient evidence for causation and these variants were classified as variants of unknown significance instead of likely pathogenic. In addition, Table [2](#Tab2){ref-type="table"} presents the allele frequencies of the variants in the Dutch population derived from the GoNL cohort which contains data from parent--child combinations (Genome of the Netherlands [@CR10]). From this source, only the information from the parents (*n* = 499) was used to compare the minor allele frequency (MAF) in the Dutch population to the allele frequencies derived from Alamut. We choose to add this information because the study population was predominantly (≥95 %) of Dutch ancestry and population-specific allele frequencies may help categorization of variants. Familial segregation of the variants with aneurysms in families was examined when affected relatives were available and consented for DNA testing.Table 1Classification of variantsClassVariantBenignFrequency in population ≥0.01Likely benignIntronic or silent variants with no effect on splicing, missense variants for which 4/5 or 3/4 in silico protein predictions are neutralUnknown significanceIntronic, silent or missense variants that affect splicing, in-frame deletions/insertions, missense variants for which more than 2 in silico protein predictions are damagingLikely pathogenicFrameshift, nonsense or intronic variants that affect splicing in a way that a new in-frame protein is created, missense variants that have previously been linked to disease in HGMDPathogenicFrameshift, nonsense or intronic variants that affect splicing in a way that no in-frame protein can be createdTable 2Variants in familial and sporadic abdominal aortic aneurysmGene/variantProtein changedbSNP IDMAF/MACSplice site predictionPredicted pathogenic effect on protein (in silico,*n* programs)Amino acid conservation (*n* species)ClassificationNumber of variants (familial/sporadic AAA) (99/56)Segregation^a^MAF GoNL^b^***COL3A1**3 (3/0)*** c.812G\>A (Pickup and Pollanen [@CR34])^c^p.Arg271Glnrs1121858870.001/1No effect2/5Moderately conserved (9)VUS1 (1/0)nd0.004 c.898-14A\>GIntronic----Effect----VUS1 (1/0)ndna** c.1471C\>Tp.Arg491X----No effect----P1 (1/0)+na*EFEMP2**6 (6/0)*** c.160+17G\>TIntronic----No effect----LB1 (1/0)ndna c.277G\>A^c^p.Gly93Serrs22344620.001/3No effect0/4Moderately conserved (10)LB3 (3/0)−/nd0.005 c.368-4G\>AIntronicrs1115509730.002/4No effect----LB1 (1/0)−0.007 c.1047C\>T^c^no-change----No effect----LB1 (1/0)ndna***FBN1**8 (5/3)*** c.59A\>G (Arbustini et al. [@CR2])^c,d^p.Tyr20Cysrs201309310--No effect0/4Moderately conserved (11)VUS1 (0/1)na c.248-17C\>G^c^Intronic----No effect----LB1 (1/0)−na c.1108G\>A^c^p.Val370lle----No effect0/5moderately conserved (11)LB1 (1/0)ndna c.2260T\>C^c^p.Tyr754His----No effect4/5highly conserved (11)VUS1 (1/0)ndna c.2895G \> A^\#^no-changers140591--No effect----LB1 (1/0)ndna c.3455C\>T (Hung et al. [@CR15])^d^p.Ala1152Val----Effect1/5Highly conserved (11)VUS1 (0/1)na c.6055G\>A (Sheikhzadeh et al. [@CR42])^d^p.Glu2019Lys----No effect3/5Highly conserved (11)VUS1 (1/0)nd0.001 c.7412C\>Gp.Pro2471Argrs193922233--No effect3/5Highly conserved (11)VUS1 (0/1)na***MYH11**11 (9/2)* c.760C\>T** (Kuang et al. [@CR20])^a^**p.Arg254Cysrs1507594610.001/2No effect3/4Highly conserved (13)LP1 (1/0)+0.008** c.956A\>Gp.Asn319Serrs149964928--Effect1/4Highly conserved (13)VUS1 (1/0)−na c.1523G\>Ap.Arg508Hisrs1442442390.001/2No effect3/4Highly conserved (13)VUS1 (1/0)ndna c.1868C\>Gp.Ala623Glyrs140688587--No effect1/4highly conserved (13)LB1 (1/0)−na c.2881-14C\>GIntronic----No effect----LB1 (1/0)+na c.4694C\>T^c^p.Thr1565Metrs1118545630.001/1No effect3/4Moderately conserved (13)VUS1 (1/0)gem0.004 c.5587C\>T^c^no-changers142639688--No effect----LB1 (1/0)nd0.004 c.5635-7G\>A^c^Intronicrs2021207920.001/1No effect----LB2 (1/1)ndna c.5697G\>C^c^p.Glu1899Asprs1139641730.005/10No effect4/4Highly conserved (13)VUS1 (1/0)−0.008 c.5808-11\_-8delIntronic----Effect----VUS1 (0/1)na***MYLK**19 (13/6)*** c.312T\>Cno-changers147597398--No effect----LB1 (1/0)gemna c.745T\>Gp.Ser249Ala----No effect2/5Highly conserved (7)VUS1 (0/1)na c.1314C \> Tno-changers2004239540.001/2No effect----LB1 (0/1)0.001 c.1327C\>T^c^p.Pro443Serrs351563600.006/13No effect4/5Highly conserved (7)VUS4 (4/0)-/nd0.014 c.2101G \> Ap.Ala701Thrrs1428355960.003/7No effect2/5Highly conserved (7)VUS1 (0/1)na c.3184G\>T^c^p.Ala1062Serrs11558550--No effect0/5Highly conserved (7)LB1 (0/1)na c.3302A\>G^\#^p.Lys1101Arg----No effect0/5Highly conserved (7)LB1 (1/0)−na c.3403G\>Ap.Gly1135Arg----No effect4/5Highly conserved (7)VUS1 (1/0)+na c.3583A\>G^c^p.Asn1195Asp----No effect3/5Highly conserved (7)VUS1 (1/0)ndna c.4179C\>Tno-change----No effect----LB2 (1/1)−na c.4764G\>A^c^no-changers560568230.003/6No effect----LB3 (2/1)nd0.008 c.4785C\>Tno-change----No effect----LB1 (1/0)ndna c.5079G\>A^c^no-changers1414676750.002/5No effect----LB1 (1/0)ndna***TGFB2**2 (2/0)*** c.272G\>A^c^p.Arg91Hisrs104827210.001/3No effect3/4Highly conserved (12)VUS1 (1/0)nd0.005 c.703G\>Cp.Val235Leurs104828100.001/2No effect2/4highly conserved (12)VUS1 (1/0)nd0.006***TGFBR1**5 (4/1)*** c.15C\>T^c^no-change----No effect----LB1 (1/0)ndna c.214A\>Tp.Ile72Leurs111513627--No effect2/5Highly conserved (12)VUS2 (1/1)−na c.927G\>C^c^no-change----No effect----LB1 (1/0)ndna c.1125A\>C^c^no-changers78617800.003/6No effect----LB1 (1/0)nd0.004***TGFBR2**3 (2/1)*** c.1137C\>Tno-changers113194608--No effect----LB1 (1/0)+0.004 c.1234G\>A (Matyas et al. [@CR28])^c,d^p.Val412Metrs357666120.001/1No effect3/4Highly conserved (14)VUS1 (1/0)gem0.002** c.1573delA** ^**c**^**p.Ile525Phefs\*18----No effect----P1 (0/1)na**In bold the variants classified pathogenic or likely pathogenic*P* pathogenic, *LP* likely pathogenic, *VUS* variant of unknown clinical significance, *LB* likely benign, *MAF* minor allele frequency, *MAC* minor allele count, *na* not applicable^a^ For familial AAA, segregation of the variant in affected relatives was investigated, (+) variant present in all affected relatives in one family, (−) variant did not segregate in a family with AAA, (nd) segregation of the variant in familial AAA was not determined, (gem) affected gemelli with variant^b^ Frequency in GoNL based on 499 studied individuals, 998 alleles, (na) variant was not reported in GoNL data^c^ Variant is involved in complex genotypes^d^ Variant reported in aneurysm patient in HGMD

Results {#Sec5}
=======

Forty-seven variants were detected in 31 familial AAA (31 %) patients and 12 sporadic AAA (21 %) patients in *COL3A1, EFEMP2, FBN1, MYH11, MYLK*, *TGBF2, TGFBR1*, and *TGFBR2*, no variants were found in *ACTA2* and *SMAD3* (Table [2](#Tab2){ref-type="table"}).

Pathogenic variants {#Sec6}
-------------------

Two variants were classified as pathogenic. A *COL3A1* null mutation p.Arg491X was observed, segregating in patients with aneurysms in one family. This null mutation was observed in a 49-year-old man diagnosed with a small dissection of the arteria lienalis at screening for familial abdominal aneurysms (Supplementary online table). His paternal aunt who had a successful repair of an infrarenal aneurysm at age 69 also had the mutation. Her brother was reported with a sudden death at age 32 years. No autopsy was performed. Screening for the *COL3A1* mutation detected one asymptomatic 50-year-old female carrier without signs of vascular pathology on computed tomography angiography. None of the carriers of the null mutations showed distinct loss of subcutaneous fat, skin fragility, abnormal scarring or suffered from complications or bleeding after surgery or childbirth.

A novel heterozygous single base pair deletion in *TGFBR2*, p.Ile525Phefs\*18 was found de novo in a 47-year-old male presenting with complex vascular pathology. This patient presented at the emergency room with severe acute abdominal pain and was diagnosed with a Stanford type-B aortic dissection associated with a pre-existing large aorto-iliac aneurysm and marked aorta-iliacal aneurysm with tortuosity with a diameter of 98.5 mm. The ascending aortic diameter was normal measuring 32.0 mm. The patient was treated with β-blockade and blood pressure control, resulting in complete remission of symptoms. Two weeks after onset of the symptoms, the aorto-iliac aneurysm was successfully repaired with an aorto-bifemoral Dacron bypass (van de Luijtgaarden et al. [@CR48]). Marked arterial elongation and tortuosity of the abdominal aorta and iliac arteries was present without characteristic facial or musculo-skeletal signs of the Loeys--Dietz or Marfan syndrome. DNA analysis of his parents showed that the mutation occurred de novo and no other relatives were affected. This patient also had a likely benign *MYH11* intronic variant c.5635-7G \> A just before exon 40. The likely benign *MYH11* variant occurred also in his two unaffected sisters and their 74-year-old unaffected father.

Likely pathogenic variants {#Sec7}
--------------------------

The missense variant in *MYH11* (p.Arg254Cys) was classified as likely pathogenic because a report showing pathogenic effects was available (Kuang et al. [@CR20]). This variant was initially detected in a 73-year-old woman with a symptomatic abdominal aneurysm. The mutation was also present in her 44-year-old son diagnosed by family screening with bilateral aneurysm of the iliac arteries and a small abdominal aneurysm.

Variants of unknown significance (VUS) {#Sec8}
--------------------------------------

Twenty-one VUS included 19 missense and 2 intronic variants. In familial cases 15 VUS were observed; 14 missense and one intronic. In sporadic cases, 7 VUS were observed; 6 missense and one intronic. Two VUS were present in multiple patients. The *MYLK* (p.Pro443Ser) variant was found in four patients with familial AAA, but this variant did not segregate in one family and segregation could not be tested in the other families. The *TGFBR1* (p.Ile72Leu) variant was present in one sporadic and one familial case, and did not segregate. Three VUS variants in *FBN1* (p.Tyr20Cys, p.Ala1152Val, and p.Glu2019Lys) were previously reported in patients with Marfan syndrome, without sufficient evidence to be classified as likely pathogenic (Arbustini et al. [@CR2]; Hung et al. [@CR15]; Sheikhzadeh et al. [@CR42]). The *TGFBR2* (p.Val412Met) variant in two affected twin brothers was previously reported in thoracic aneurysm (Matyas et al. [@CR28]). The VUS missense variant in *COL3A1* (p.Arg271Gln) was previously linked to Ehlers--Danlos syndrome in the literature, however, after critical evaluation of the report, the evidence for this link was considered not sufficient to classify the variant as pathogenic (Pickup and Pollanen [@CR34]).

Likely benign variants (LB) {#Sec9}
---------------------------

Of the twenty-three likely benign variants five were intronic, 13 were synonymous and 5 were missense variants. Four LB variants were observed in more than one patient: the synonymous *MYLK* c.4764G\>A was present in three patients (two familial, one sporadic), the synonymous *MYLK* c.4179C\>T and the intronic variant *MYH11* c.5635-7G\>A occurred in one familial and one sporadic patient, and the missense *EFEMP2* p.Gly93ser was present in three patients with familial AAA without evidence of segregation.

MTHFR c.665C\>T {#Sec10}
---------------

The *MTHFR* c.665C\>T (p.Ala222Val) variant, previously reported as C677T, was tested in 130 patients (89 familial and 41 sporadic AAA patients). Twelve patients (9 %) were homozygous for the variant allele: ten (11 %) familial and two (5 %) sporadic. Forty-five (38 %) patients were heterozygous for the variant allele: thirty one (35 %) familial and fourteen (34 %) sporadic patients. The MAF in our study population was 0.265 compared to 0.320 in the Dutch GoNL cohort (Table [3](#Tab3){ref-type="table"}).Table 3Frequencies of the *MTHFR* c.665C\>T variant in AAA and control populationsReferencesPatients (*N*)DiagnosisMAFNormal (CC)Heterozygote (CT)Homozygote (TT)CT and TTBrunelli et al. ([@CR6])58AAA0.48314 (24 %)32 (55 %)12 (21 %)44 (76 %)60Control0.39219 (32 %)35 (58 %)6 (10 %)41 (68 %)Strauss et al. ([@CR44])63AAA0.36521 (33 %)38 (60 %)4 (6 %)42 (67 %)75Control0.23149 (65 %)20 (27 %)6 (8 %)26 (35 %)Jones et al. ([@CR16], [@CR17])428AAA^a^0.310211 (49 %)169 (40 %)48 (11 %)217 (51 %)282Control (healthy)0.309134 (48 %)122 (43 %)26 (9 %)148 (52 %)271Control (CVD)0.303137 (51 %)104 (38 %)30 (11 %)134 (49 %)226Control (PAD)0.332106 (47 %)90 (40 %)30 (13 %)120 (53 %)Sofi et al. ([@CR43])438AAA0.430141 (32 %)217 (50 %)80 (18 %)297 (68 %)438Controls0.380166 (38 %)211 (48 %)61 (14 %)272 (62 %)Ferrara et al. ([@CR9])42AAA \> 60 years0.29818 (43 %)23 (55 %)1 (2 %)24 (57 %)46AAA \< 60 years0.42410 (22 %)33 (72 %)3 (6 %)36 (78 %)45Control0.13334 (75 %)10 (23 %)1 (2 %)11(24 %)Current study130AAA total0.265^a^73 (56 %)45 (35 %)12 (9 %)57 (44 %)89AAA familial0.28748 (54 %)31 (35 %)10 (11 %)41 (46 %)41AAA sporadic0.22025 (61 %)14 (34 %)2 (5 %)16 (39 %)Overall1205AAA0.364488 (40 %)557 (46 %)160 (13 %)717 (60 %)1397Control0.326645 (46 %)592 (42 %)160 (11 %)752 (54 %)^a^MAF in Dutch population: 0.320

Complex genotypes {#Sec11}
-----------------

Thirteen AAA patients (11 familial, including one pair of concordant monozygotic twins, and 2 sporadic) had two or more variants (Table [4](#Tab4){ref-type="table"}). One pathogenic *TGFBR2* was involved in a complex genotype with a likely benign variant in *MYH11.*Table 4AAA patients with multiple variants in aneurysm genesPatientFamilial/sporadic AAACOL3A1EFEMP2FBN1MTHFRMYH11MYLKTGFB2TGFBR1TGFBR21.Familial----LB c.1108G\>A--------LB c.15C \> T--2.Sporadic----VUS c.59A\>G----LB c.3184G\>T------3.Familial----LB \_c.2895G\>A----VUS c.4764G\>A------4.^b^Familial--------VUS c.4694C\>T----VUS c.1234G\>A5.Sporadic--------LB c.5635-7G\>A------**P c.1573delA** ^a^6.Familial--------VUS c.5697G\>C--LB c.1125A\>C--7.Familial--LB c.277G\>A------LB c.3302A\>G------8.^b^FamilialVUS c.812G \> A--------VUS c.1327C\>T------9.Familial--LB c.277G\>A----LB c.5587C\>TVUS c.1327C\>T------10.Familial----LB c.248-17C\>G--VUS c.956A\>G--------11.Familial--LB c.1047C\>T and (3)c.277G\>A----------LB c.927G\>C--12.^b^Familial----VUS c.2260T\>C------VUS c.272G\>A----13.Familial----------LB c.3583A\>G and VUS c.5079G\>A------Variants of class 4 or higher are shown in bold*P* pathogenic, *LP* likely pathogenic, *VUS* variant of unknown clinical significance, *LB* likely benign^a^ de novo mutation^b^ Patient with multiple variants of VUS or higher

Frequency of variants in the Dutch population {#Sec12}
---------------------------------------------

For 16 of the variants found in this study, the allele frequency in the Dutch population was available from GoNL. The MAF of the VUS variant in *MYLK* (p.Pro443Ser) was 0.014 in the Dutch population, and was reported in dbSNP with an MAF of 0.006. This indicates that this variant would be reclassified as a benign variant, using the GoNL frequency information instead of the frequency reported by dbSNP/ESP used in Alamut.

Discussion {#Sec13}
==========

The genetic defects causing familial abdominal aortic aneurysm are poorly understood. This study showed that genes known to be associated with inherited thoracic aortic aneurysm also have a role in abdominal aortic aneurysm. Our study is based on a group of AAA patients referred for counseling. Therefore, the observed results do not represent prevalence of variants in the Dutch AAA population. Although familial cases were overrepresented in the current study, a referral bias for genotype can be excluded, since there was no prior information on genetic defects in familial or sporadic AAA. The validation of our family history data showed that no relatives were reported incorrectly as affected, indicating that risk in relatives was not overestimated. On the other hand, underreporting of familial disease may have happened, in particular for a disease like AAA, where aneurysms in relatives may go unnoticed and relatives could have undiagnosed aneurysms or may have died before age of onset. It is, therefore, important to bear in mind that familial AAA cannot be excluded when family history of aneurysm is uninformative or missing.

This study investigated the association between AAA and the thoracic aneurysm genes *ACTA2*, *COL3A1, EFEMP2, FBN1, MYH11, MYLK*, *SMAD3*, *TGBF2, TGFBR1*, *TGFBR2,* and *MTHFR* (p.Ala222Val). There have been several large GWAS studies that found AAA risk alleles in *LRP1*, (Bown et al. [@CR5]) *DAP21P*, (Gretarsdottir et al. [@CR11]) *ANRIL*, (Helgadottir et al. [@CR13]) and *SORT1* (Jones et al. [@CR17]). These genes have not been tested in this study, but it would be useful to do so in future studies.

In this study, three variants were observed classified as pathogenic or likely pathogenic amongst a total of 47 unique rare variants in our AAA study population of 155 patients. Lack of a comprehensive overview of genetic variants in thoracic aneurysms precluded comparison of our findings in the abdominal aneurysm population to thoracic aneurysms population.

Assessment of pathogenicity of genetic variants remains a major challenge (MacArthur et al. [@CR26]). Comprehensive guidelines are needed to distinguish true pathogenic from ambiguous variants with unknown clinical significance which constitutes a large part of the results of molecular analyses (Richards et al. [@CR39]). Variants are listed in HGMD which reports whether variants and/or genes have been described in the literature as associated with disease requiring critical review of evidence presented to justify classification as likely pathogenic. Additional searches may be needed because not all known variants are listed in HGMD. Establishing a causal effect of variants involves finding a method of choice for functional testing of variants in aneurysm genes, which is complicated giving the likelihood of tissue-specific gene expression. Especially since nowadays abdominal aortic aneurysms are mostly restored by an endovascular procedure, no aortic aneurysm tissue from patients can be collected for functional testing.

Alamut incorporates allele frequency reported by dbSNP/ESP. The use of population-specific control cohorts, as GoNL in the current study, may improve correct classification of variants and prevent associating population-specific polymorphisms with disease.

Significant co-segregation of a variant with disease provides evidence to support pathogenicity. In our study population it was often not possible to detect co-segregation because AAA is a late onset disorder, where the majority of patients, familial AAA and sporadic AAA alike, are older than 65 years and most affected relatives are no longer alive. Although our results suggest that more variants occur in familial cases (31 %) than in sporadic cases (21 %), the available sample size of the study population did not provide sufficient statistical power to test the difference between familial and sporadic AAA (Table [5](#Tab5){ref-type="table"}).Table 5Genetic variants in 99 familial and 56 sporadic abdominal aortic aneurysm patientsGene/variantsTotal AAA patientsFamilial AAA patientsSporadic AAA patients*p* value*n*ALLLP/P*n*ALLLP/P*n*AllLP/PALLLP/PACTA2139009200470011COL3A11223 (2 %)1 (1 %)823 (2 %)1 (1 %)400011EFEMP2895 (7 %)0655 (8 %)024000.191FBN11278 (6 %)0855 (6 %)0423 (7 %)011MYH1113311 (8 %)1 (1 %)909 (10 %)1 (1 %)432 (5 %)00.501MYLK13618 (13 %)09012 (13 %)0466 (13 %)011SMAD3142009400480011TGFB2652 (3 %)0402 (5 %)025000.521TGFBR11415 (4 %)0934 (4 %)0481 (2 %)00.661TGFBR21403 (2 %)1 (1 %)942 (2 %)0461 (2 %)1 (2 %)10.33*LP* likely pathogenic, *P* pathogenic, All variants: pathogenic, likely pathogenic, unknown clinical significance and likely benign\**P* value was calculated using the two-tailed Fisher's exact test

*COL3A1* {#Sec14}
--------

The vascular type of the Ehlers--Danlos syndrome has caused mutations in type III procollagen encoded by the *COL3A1* gene (Pepin et al. [@CR33]). Abnormal type III procollagen results in altered connective tissue in particular of the vascular wall, skin and inner organs. The Ehlers--Danlos type IV syndrome is associated with vascular fragility, thin and translucent skin, typical facial features, rupture uterus or intestines, and variably hypermobility or contractures. In the *COL3A1* gene we found one familial pathogenic null mutation and two VUS variants in familial AAA. Null mutations in *COL3A1* cause haploinsufficiency and were previously associated with attenuated clinical features of the vascular type of Ehlers--Danlos syndrome, like in the family described in the current study (Leistritz et al. [@CR21]).

*EFEMP2* {#Sec15}
--------

No pathogenic *EFEMP2* variants were detected in AAA patients. Four LB variants were observed in five familial AAA patients (8 %). One patient had two different variants in *EFEMP2*. One LB variant with an allele frequency of 0.005 in the Dutch population occurred in three patients.

*FBN1* {#Sec16}
------

The Marfan syndrome (MFS) was the first well-recognized genetic aortic aneurysm syndrome described in 1896, (Marfan [@CR27]) and has an estimated prevalence of 2--3 per 10,000 individuals equally affecting men and women (Pyeritz and McKusick [@CR37]). We found five *FBN1* VUS, two in familial and three in sporadic patients including three VUS previously reported in aneurysm patients in HGMD (Table [2](#Tab2){ref-type="table"}).

*MYH11* {#Sec17}
-------

One likely pathogenic segregating variant and five VUS were observed among the ten rare variants in this gene.

*MYLK* {#Sec18}
------

The *MYLK* gene harbored the most variants of all examined genes in this study in familial and sporadic patients. We found 13 unique variants in 18 patients, in 13 % of the familial and 13 % of the sporadic AAA patients. Of these variants, five were VUS and the rest was classified as likely benign.

*TGFB2* {#Sec19}
-------

Boileau and Lindsay et al. described simultaneously a mutation in the *TGFB2* gene causing familial thoracic aortic aneurysm and dissections and overlapping clinical features with Loeys--Dietz syndrome (Boileau et al. [@CR4]; Lindsay et al. [@CR22]). We observed two VUS in the *TGFB2* in two patients with familial AAA (6 %).

*TGFBR1* and *TGFBR2* {#Sec20}
---------------------

In *TGFBR1* we found variants in 4 % of familial and 2 % of sporadic patients, one VUS and three likely benign. To our knowledge no pathogenic variants in *TGFBR1* or *TGFBR2* have been linked to familial AAA. Specific alleles were previously associated with risk for AAA (Baas et al. [@CR3]; Lucarini et al. [@CR25]).

In *TGFBR2,* we found one de novo pathogenic novel single base pair deletion leading to a truncated protein. We also found one missense variant that was reported in HGMD and was classified as VUS, and one variant that we classified as likely benign.

*MTHFR* {#Sec21}
-------

The role in the susceptibility for abdominal aortic aneurysms of the *MTHFR* c.665C\>T (p.Ala222Val) variant, previously reported as C677T, was investigated by a number of case--control studies showing more robust associations in some than in others (Narayanan et al. [@CR31]). More recently, genome-wide association studies endorsed that this variant was associated with an increased risk (Brunelli et al. [@CR6]; Ferrara et al. [@CR9]; Jones et al. [@CR16]; Sofi et al. [@CR43]; Strauss et al. [@CR44]). In the current study, the MAF of the risk allele was lower (0.265) than in the Dutch control population (0.320), indicating that our data did not support a link with AAA.

Concluding remarks {#Sec22}
==================

This study identified three causal variants in a set of genes previously associated with familial thoracic aortic aneurysms in 155 familial and sporadic AAA patients. Our results showed that diagnostic testing of these aneurysm genes might help find the cause for AAA and help to accurately identify relatives at risk. It is important to note the occurrence of de novo mutations, indicating that a negative family history should not preclude genetic testing. Pathogenic variants were found in two younger male patients with complex vascular features and an elderly female AAA patient. Although we cannot exclude an effect of referral bias, these observations merit further studies addressing the question whether age, gender and clinical features define a risk profile for molecular defects in AAA patients.

The identification of 44 other variants in genes associated with hereditary thoracic aneurysms suggests a more important contribution of these genes in AAA than known before. We expect that additional aneurysm-associated genes will be detected in the future because the majority of familial AAA patients had no variants in the examined genes.
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